News Sentiment

INTS sentiment intelligence

Intensity Therapeutics, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.78 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+12.7% over one week, +32.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 12.7% Price confirming higher
Trend fit Trend inactive 32.0% over four weeks
Fair value -92.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 39
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Market source 9
PR Newswire 7
Stock Titan 6
TradingKey 5
Investing.com 3
Quiver Quantitative 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 21
Analyst action 4
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Investing.com Direct company coverage

Intensity Therapeutics resumes patient dosing in Swiss trial

Intensity Therapeutics Inc. has resumed patient dosing in its INVINCIBLE-4 Study in Switzerland for early-stage, operable triple-negative breast cancer, following a temporary pause due to skin irritation. The company's stock has faced volatility, but analysts maintain a bullish o

Tone
Positive 65/100
Event
Market update
Published
15 Jul 2026 12:39
Source
Investing.com
PR Newswire Direct company coverage

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics has restarted patient treatment in its Phase 2 clinical trial (INVINCIBLE-4 Study) for presurgical triple-negative breast cancer (TNBC) in Switzerland. The trial, using INT230-6, was resumed after a protocol amendment addressed skin irritation issues by adj

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 11:39
Source
PR Newswire
Stock Titan Direct company coverage

INTS SEC Filings - INTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for SEC filings related to Intensity Therapeutics (Ticker: INTS), a clinical-stage biotechnology company. It includes access to 10-K, 10-Q, 8-K reports, and insider trading forms, with the most recent filing being a Form 4 on July 2, 20

Tone
Positive 66/100
Event
Market update
Published
03 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount

Intensity Therapeutics' Chief Financial Officer, Joseph Talamo, acquired 1,093 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $3.485 per share. This purchase, made on June 30, 2026, increased his direct holdings to 2,239 shares

Tone
Positive 58/100
Event
Market update
Published
01 Jul 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer

John M. Wesolowski, Principal Accounting Officer at Intensity Therapeutics (NASDAQ: INTS), acquired 3,688 shares through the company's Amended and Restated 2024 Employee Stock Purchase Plan. The shares were purchased at $3.485 each, increasing his direct holdings to 7,102 shares.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:40
Source
Stock Titan
grafa.com Direct company coverage

Intensity Therapeutics updates INT230-6 cancer trials

Intensity Therapeutics (NASDAQ:INTS) has provided a mid-year update on its INT230-6 cancer therapy, detailing advancements in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials. Preliminary data from triple-negative breast cancer studies showed improved pathological c

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 12:20
Source
grafa.com
PR Newswire Direct company coverage

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Intensity Therapeutics has issued a mid-year update for 2026, detailing the advancement of its late-stage development programs for INT230-6 in soft tissue sarcoma and presurgical triple-negative breast cancer. The company highlights favorable preliminary clinical observations, si

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 11:40
Source
PR Newswire
Stock Titan Direct company coverage

Intensity Therapeutics resumes cancer trials, seeks INT230-6 partners

Intensity Therapeutics provided a mid-year 2026 update on its INT230-6 intratumoral cancer therapy, highlighting progress in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials. The company reported peer-reviewed data, active partnering discussions, and established a $

Tone
Positive 84/100
Event
Market update
Published
30 Jun 2026 06:12
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Intensity Therapeutics, Inc. – NASDAQ:INTS

This page from TradingView displays financial information for Intensity Therapeutics, Inc. (NASDAQ: INTS), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with SE

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Intensity Therapeutics, Inc. – NASDAQ:INTS

This article provides a brief financial overview of Intensity Therapeutics, Inc. (NASDAQ: INTS), focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication, with no trades occurring. The content is presented within the Trading

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS)

This article provides an overview of Intensity Therapeutics, Inc. (NASDAQ: INTS) stock performance, financial estimates, and analyst forecasts. It covers current stock price, volatility, market capitalization, upcoming earnings dates, and historical financial data such as revenue

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Intensity Therapeutics, Inc. Actuals & Estimates (BOATS:INTS)

This article provides financial actuals and estimates for Intensity Therapeutics, Inc. (INTS) traded on BOATS. It includes information on the stock ticker, analyst price forecasts ranging from $12.00 to $32.00, historical high and low prices, upcoming earnings reports, and detail

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Intensity Therapeutics, Inc. – NASDAQ:INTS

This article displays the "Enterprise value to revenue forward" metric for Intensity Therapeutics, Inc. (NASDAQ: INTS). It appears to be a financial data point from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet. The conten

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

INTS Forecast — Price Target — Prediction for 2027

This article provides a forecast for Intensity Therapeutics, Inc. (INTS) stock, including analyst price targets, current stock performance, and financial data. It highlights that analysts have a maximum price estimate of $32.00 and a minimum of $12.00 for INTS. The piece also inc

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 18:10
Source
TradingView
The Globe and Mail Direct company coverage

Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting

Intensity Therapeutics, Inc. held its annual meeting where stockholders approved several key proposals. These included the election of two Class III directors, ratification of EisnerAmper LLP as independent public accounting firm, and approval of amendments to stock incentive pla

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 Jun 2026 21:09
Source
The Globe and Mail
TradingKey Direct company coverage

Intensity Therapeutics Inc (INTS) Institutional Confidence

The article provides an overview of institutional confidence in Intensity Therapeutics Inc (INTS), detailing key institutional shareholders and their recent activity. It lists the shares held and the percentage change for several firms, including Bender (Lewis H), Sapient Capital

Tone
Positive 76/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Intensity Therapeutics Inc (INTS) has a "Buy" rating from 5 analysts, with a target price of $3.00, representing a significant upside. The company's previous quarter's EPS was -$1.31, missing the market expectation of -$0.96, but the next quarter's EPS is projected to be -$0.77.

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Intensity Therapeutics Inc. (INTS), focusing on its PE, PB, and fair value. However, it notes that relevant data for these metrics have not yet been disclosed by the company, limiting a comprehensive valuation based on these specific

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey
Investing.com Direct company coverage

Intensity Therapeutics shareholders approve board proposals at annual meeting

Intensity Therapeutics (NASDAQ:INTS) shareholders approved all proposals at their annual meeting, including the election of two Class III directors, the ratification of EisnerAmper LLP as the accounting firm, and amendments to the 2021 Stock Incentive Plan and 2024 Employee Stock

Tone
Positive 66/100
Event
Market update
Published
17 Jun 2026 20:09
Source
Investing.com
TradingKey Direct company coverage

Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses Intensity Therapeutics Inc (INTS) and its revenue breakdown by business segments and regions. However, the core message is that the relevant financial data for these breakdowns has not yet been disclosed by the company. The article provides current stock inf

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 19:41
Source
TradingKey
TradingKey Direct company coverage

Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Intensity Therapeutics Inc (INTS) shareholder structure, listing major individual and institutional holders and their respective proportions. It also includes institutional shareholding trends over several quarters and recent sharehol

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 18:41
Source
TradingKey
Investing.com South Africa Direct company coverage

Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com

Intensity Therapeutics shareholders have approved all proposals at their annual meeting, including the election of two Class III directors, ratification of their accounting firm, and amendments to their stock incentive and employee stock purchase plans. This comes as the biotech

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 23:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections

Intensity Therapeutics, Inc. (NASDAQ: INTS) held its 2026 annual stockholder meeting, where shareholders approved increases to the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan. Shareholders also elected Dr. Emer Leahy and Lewis H. Bender as Class III directors

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote

Intensity Therapeutics, Inc. (INTS) held its AGM 2026 where all proposals were approved by a majority vote. This included the re-election of two directors, the ratification of the auditor, and amendments to stock plans. No questions were raised during the Q&A session.

Tone
Positive 69/100
Event
Market update
Published
16 Jun 2026 15:10
Source
TradingView